SAGE Therapeutics (SAGE) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
May 2, 2019 6:30 AM EDTZULRESSO (brexanolone) injection approved by U.S. FDA and on track for launch in late June
Commercial team is launch ready; field teams focusing on payer engagement and identifying pathways to care
Strong financial position with ~$1.4B in cash
Milestones anticipated throughout 2019 in clinical studies across all three franchises: depression, neurology and neuropsychiatry
Conference call today at 8:00 A.M. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc.(NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat... More
